2021年7月至8月欧洲Delta变异株流行期间在初级保健和社区层面完整基础免疫接种对COVID-19的有效性:多中心分析,I-MOVE-COVID-19与ECDC网络
2021年7月至8月Delta变异株在欧洲流行期间,在10个欧洲国家初级保健/社区层面开展多中心检测阴性设计研究,评估COVID-19疫苗对症状性感染的有效性。完整基础免疫总体疫苗有效性(VE)为74%(95%CI:69-79)。VE因疫苗品牌和年龄组而异,范围52%至91%;Comirnaty在接种后90天及以上VE为65%。
要点
- 30-59岁人群中,Comirnaty、Vaxzevria、Spikevax和COVID-19 Vaccine Janssen的VE分别为78%、66%、91%和52%。
- 60岁及以上人群中,Comirnaty、Vaxzevria和Spikevax的VE分别为67%、65%和83%。
- Comirnaty在30-59岁人群中接种后14-29天VE为87%,≥90天为65%。
核心结论
- 针对SARS-CoV-2 Delta变异株症状性感染的VE因疫苗品牌而异,范围为52%至91%。
- 虽然可能存在疫苗效果减弱(样本量限制该分析仅纳入Comirnaty),但接种与症状出现间隔90天或以上时保护力为65%。
研究设计与样本
- 多中心检测阴性研究,在10个欧洲国家初级保健/社区层面对有COVID-19或急性呼吸道症状者进行SARS-CoV-2检测。
- 测量完整基础免疫接种的总体VE,按疫苗品牌和接种后时间分析。
主要发现
- 总体VE为74%(95%CI:69-79)。
- 30-44岁、45-59岁、60-74岁和≥75岁人群VE分别为76%(95%CI:71-80)、63%(95%CI:48-75)和63%(95%CI:16-83);原文此处写作30-44岁VE 76%、45-59岁VE 63%、60-74岁VE 63%(95%CI:16-83),按上下文60-74岁与≥75岁的VE数值及置信区间对应关系应为60-74岁63%(95%CI:48-75)、≥75岁63%(95%CI:16-83)。
- 30-59岁人群中,Comirnaty、Vaxzevria、Spikevax和COVID-19 Vaccine Janssen的VE分别为78%(95%CI:75-81)、66%(95%CI:58-73)、91%(95%CI:87-94)和52%(95%CI:40-61)。
- 60岁及以上人群中,Comirnaty、Vaxzevria和Spikevax的VE分别为67%(95%CI:52-77)、65%(95%CI:48-76)和83%(95%CI:64-92)。
- 30-59岁人群中,Comirnaty接种后14-29天VE为87%(95%CI:83-89),≥90天VE为65%(95%CI:56-71%)。
局限性
- 样本量限制,疫苗效果减弱分析仅纳入Comirnaty。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IntroductionIn July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe.AimUsing a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection.MethodsIndividuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination.ResultsOverall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms.ConclusionsVE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.
引用
- Kissling E, Hooiveld M, Martínez-Baz I, et al. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. Euro Surveill. 2022. PMID: 35620997. doi:10.2807/1560-7917.ES.2022.27.21.2101104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。